31.75

3.44% -1.145

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $31.75, with a volume of 447.53K. It is down -3.44% in the last 24 hours and down -24.51% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.

Previous Close:

$32.89

Open:

$32.53

24h Volume:

447.53K

Relative Volume:

0.39

Market Cap:

$1.95B

Revenue:

$13.05M

Net Income/Loss:

$-60.54M

P/E Ratio:

-27.37

EPS:

-1.16

Net Cash Flow:

$-37.82M

1W Performance:

-5.42%

1M Performance:

-24.51%

6M Performance:

-29.44%

1Y Performance:

-33.38%

1-Day Range:

$31.72

$33.49

1-Week Range:

$31.69

$34.08

52-Week Range:

$31.69

$71.71

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	31.75	1.95B	13.05M	-60.54M	-37.82M	-1.16
VRTX Vertex Pharmaceuticals Inc	490.47	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.19	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	634.93	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.25	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.59	27.34B	3.30B	-501.07M	1.03B	-2.1146

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Mar 01, 2025

Janux Therapeutics price target lowered to $41 from $62 at Scotiabank - Yahoo Finance

Mar 01, 2025

Feb 28, 2025

Janux Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Feb 28, 2025

Janux Therapeutics (NASDAQ:JANX) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat

Feb 28, 2025

Analyst Recommends ‘Buy’ for Janux Therapeutics Inc. Amid Share Price Decline and Promising Clinical Outlook - TipRanks

Feb 28, 2025

Promising Potential of Janux Therapeutics’ Lead Asset and Strategic Plans Justify Buy Rating - TipRanks

Feb 28, 2025

(JANX) Technical Data - Stock Traders Daily

Feb 28, 2025

Wedbush Adjusts Price Target on Janux Therapeutics to $76 From $75, Maintains Outperform Rating - Marketscreener.com

Feb 28, 2025

Cantor Fitzgerald maintains $200 target on Janux Therapeutics stock By Investing.com - Investing.com UK

Feb 28, 2025

Feb 27, 2025

Janux Therapeutics reports Q4 EPS (36c), consensus (45c) - TipRanks

Feb 27, 2025

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - Business Wire

Feb 27, 2025

Feb 25, 2025

Janux Therapeutics stock hits 52-week low at $33.29 - Investing.com

Feb 25, 2025

Janux Therapeutics stock hits 52-week low at $33.29 By Investing.com - Investing.com Canada

Feb 25, 2025

Janux Therapeutics Insiders Sold US$6.9m Of Shares Suggesting Hesitancy - Simply Wall St

Feb 25, 2025

Feb 24, 2025

Janux Therapeutics Enters Oversold Territory (JANX) - Nasdaq

Feb 24, 2025